Please assess the completion status of the following clinical trial:

Trial Title: Pharmacological Cognitive Enhancement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* subjects do not meet the criteria for exclusion~Exclusion Criteria:~* current signs of psychiatric, neurological or medical (hypertension, cardiac disorders, epilepsy) conditions as determined by the Millon test and by clinical examination;subjects showing visual or motor impairments. All subjects taking any psychoactive drug or having a history of alcohol abuse.

- Gender: MALE
- Minimum Age: 25 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: EXPERIMENTAL): Study subjects received, in a double blind fashion, a placebo pill identical to the drug.
- Modafinil (Type: EXPERIMENTAL): Modafinil (Provigil), a drug on the market since 1997, is employed for the treatment of narcolepsy and other sleep disorders. In recent years, modafinil has also been used off-label to treat cognitive dysfunction in psychiatric disorders such as schizophrenia and Attention Deficit/Hyperactivity Disorder (ADHD).~Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil.

Based on this trial design, predict the completion outcome and termination type (if applicable).